EMERYVILLE, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today members of its Executive Team will participate at the following September 2024 investor conferences:
XOMA’s presentations can also be accessed by visiting the investor relations section of the Company’s website at www.xoma.com. A replay of each presentation will be available and archived on the site for 90 days after the event.
About XOMA Royalty Corporation
XOMA Royalty is a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health. XOMA Royalty acquires the potential future economics associated with pre-commercial and commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. When XOMA Royalty acquires the future economics, the seller receives non-dilutive, non-recourse funding they can use to advance their internal drug candidate(s) or for general corporate purposes. The Company has an extensive and growing portfolio of assets (asset defined as the right to receive potential future economics associated with the advancement of an underlying therapeutic candidate). For more information about the Company and its portfolio, please visit www.xoma.com or follow XOMA Royalty Corporation on LinkedIn.
XOMA Investor Contact Juliane Snowden XOMA Royalty +1 646-438-9754 This email address is being protected from spambots. You need JavaScript enabled to view it. | XOMA Media Contact Kathy Vincent KV Consulting & Management +1 310-403-8951 This email address is being protected from spambots. You need JavaScript enabled to view it. |
Last Trade: | US$24.32 |
Daily Change: | 0.88 3.75 |
Daily Volume: | 13,701 |
Market Cap: | US$286.490M |
March 17, 2025 February 24, 2025 February 04, 2025 December 02, 2024 |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREChimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load